An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Esperion (NASDAQ: ESPR) is participating in the 42nd Annual J.P. Morgan Healthcare Conference. President and CEO Sheldon Koenig will deliver a corporate presentation on January 10, 2024, at 2:15 PM PT. Esperion focuses on discovering, developing, and commercializing innovative medicines for cardiovascular and cardiometabolic diseases. The company aims to improve outcomes for patients with high cholesterol, providing the next steps to help get patients to their LDL-cholesterol level goals.
Positive
None.
Negative
None.
ANN ARBOR, Mich., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference. Sheldon Koenig, President and CEO, will deliver a corporate presentation on Wednesday, January 10, 2024, at 2:15 PM PT (5:15 PM ET). The Esperion management team will also be hosting investor meetings during the conference.
To register for the live webcast, follow this link.
A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.
When is Esperion participating in the 42nd Annual J.P. Morgan Healthcare Conference?
Esperion is participating in the 42nd Annual J.P. Morgan Healthcare Conference.
Who will deliver the corporate presentation for Esperion?
President and CEO Sheldon Koenig will deliver the corporate presentation.
What is Esperion's focus?
Esperion focuses on discovering, developing, and commercializing innovative medicines for cardiovascular and cardiometabolic diseases.
What does Esperion aim to achieve for patients with high cholesterol?
Esperion aims to improve outcomes for patients with high cholesterol, providing the next steps to help get patients to their LDL-cholesterol level goals.
esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.